Physician profile
Edward D Hirsch
NPI 1578554408
$3,395.48
in general payments reported to CMS, 2019-2025
20 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $781 · 2021: $839 · 2022: $258 · 2023: $144 · 2024: $27.68 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $876.32 | 2019-2023 | Dovato |
| Merck Sharp & Dohme LLC | $515.70 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Cipla USA INC. | $360.61 | 2019 | |
| Astellas Pharma US INC | $237.16 | 2019-2021 | |
| Abbvie INC. | $175.59 | 2021-2025 | |
| Insmed, INC. | $160.68 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $124.97 | 2023 | |
| Tetraphase Pharmaceuticals, INC. | $112.25 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $110.80 | 2021-2022 | |
| Janssen Biotech, INC. | $100.01 | 2020 | |
| Shionogi INC | $95.28 | 2020-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $92.85 | 2020-2021 | |
| Gilead Sciences, INC. | $90.16 | 2019-2021 | |
| Allergan, INC. | $79.38 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $75.61 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyera Pharmaceuticals, LLC | $75.20 | 2019-2022 | |
| Melinta Therapeutics, LLC | $47.67 | 2021 | |
| Mylan Institutional INC. | $24.79 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $21.82 | 2025 | Vibativ |
| Novo Nordisk INC | $18.63 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.